CSL Behring
CSL is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people.
475 Green Oaks Parkway
Holly Springs, NC 27540 US
Holly Springs, NC 27540 US
NEWS
It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.
Seqirus released new data that shows Fluad, an adjuvanted trivalent influenza vaccine, was more effective than standard non-adjuvanted trivalent influenza vaccine in reducing the risk of flu- and pneumonia-related hospitalization in patients 65-years-of-age and older.
Seqirus, a wholly owned subsidiary of CSL, is expanding its manufacturing plant in North Carolina. It expects to invest $140 million in the expansion.
JOBS
IN THE PRESS